Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:42:28.288Z.
Calculation as of: 2026-10-06T15:42:28.288Z.
Quote observation: 2026-10-06T15:39:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b407bf9ab9426f7f8731c51b1e955f2cfcbe23f9f3e819a9868889fb687bb4da
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Pasithea Therapeutics Corp.
Market Cap
$15.03M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.06M
EV/Sales Ratio
1.20x
TTM Avg
1.84x
3Y Avg
1.65x
5Y Avg
2.08x
Market Cap
$15.58M
EV/Sales Ratio
44.70x
TTM Avg
46.98x
3Y Avg
46.98x
5Y Avg
36.15x
Market Cap
$14.37M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.83M
EV/Sales Ratio
61.26x
TTM Avg
56.79x
3Y Avg
56.79x
5Y Avg
56.79x
Market Cap
$14.04M
EV/Sales Ratio
0.59x
TTM Avg
1.89x
3Y Avg
1.89x
5Y Avg
1.89x
Market Cap
$13.97M
EV/Sales Ratio
47.00x
TTM Avg
16.53x
3Y Avg
4.93x
5Y Avg
3.45x
Market Cap
$16.19M
EV/Sales Ratio
N/A
TTM Avg
492.25x
3Y Avg
202.04x
5Y Avg
285.29x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | $15.03M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.06M | 1.20x | 1.84x | 1.65x | 2.08x |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.58M | 44.70x | 46.98x | 46.98x | 36.15x |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.37M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.37M | N/A | N/A | N/A | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.83M | 61.26x | 56.79x | 56.79x | 56.79x |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.04M | 0.59x | 1.89x | 1.89x | 1.89x |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | 47.00x | 16.53x | 4.93x | 3.45x |
| BioCardia, Inc. (BCDA)vs › | $16.19M | N/A | 492.25x | 202.04x | 285.29x |
| IN8bio, Inc. (INAB)vs › | $13.81M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
